Derivation of Novel Murine Metastatic Pancreatic Adenocarcinoma Cell Lines to Generate Orthotopic Allograft Mouse Models Useful for Preclinical Testing

Researchers at the National Cancer Institute (NCI) have developed orthotopic allograft models for pancreatic cancer that utilize low passage primary pancreatic adenocarcinoma cells or tumor fragments implanted into the cancer-free pancreata of recipient syngeneic immunocompetent mice. Tumor development in these models is more synchronized, latency is substantially shortened, and tumors develop only in one location, as pre-determined by the choice of a site for cells/tumor fragment implantation. This technology is the firstin vivo model of metastatic pancreatic cancer utilizing an orthotopic transplantation procedure, which allows engrafting of tumor pieces into immunocompetent mice. This procedure can be used for the timed production of large cohorts of experimental animals developing pancreatic cancer for preclinical studies within a reasonable time frame and at a significant cost reduction.The NCI technology represents cell lines derived from primary pancreatic tumors and orthotopic mouse models for pancreatic cancer; cell lines and orthotopic mouse models are derived from following genotypes:KraslSL-G12D ki/+; Trp53LSL-R172H ki/+;Pdx-1-CreKrasLSL-G12D ki/+; Trp53 R172H/Koz ki/+; Pdx-1-CreKrasLSL-G12D ki/+; Trp53 R270H/Koz ki/+; Pdx-1-CreKrasLSL-G12D ki/+; Trp53 LSL-R172H ki/+; ROSA-luc4 ki/+; Pdx-1-CreKrasLSL-G12D ki/+; Pdx-1-CreIC: NCINIH Ref. No.: E-250-2017/0Advantages: Useful as a more accurate and clinically relevant experimental platform for conducting...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research